News | August 10, 2023
Hester Biosciences posts Q1 FY24 consolidated PAT at Rs. 5.86 Cr
Hester Biosciences has reported total income of Rs. 88.99 crores during the period ended June 30, 2023
Hester Biosciences has reported total income of Rs. 88.99 crores during the period ended June 30, 2023
Carbogen Amcis Manchester won the industry award in recognition of its efficiency improvement program implemented in response to increased demand for its products
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
The consideration for the acquisition is US $ 2.25 million
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)